JAK2 activation by growth hormone and other cytokines

MJ Waters, AJ Brooks - Biochemical Journal, 2015 - portlandpress.com
Biochemical Journal, 2015portlandpress.com
Growth hormone (GH) and structurally related cytokines regulate a great number of
physiological and pathological processes. They do this by coupling their single
transmembrane domain (TMD) receptors to cytoplasmic tyrosine kinases, either as
homodimers or heterodimers. Recent studies have revealed that many of these receptors
exist as constitutive dimers rather than being dimerized as a consequence of ligand binding,
which has necessitated a new paradigm for describing their activation process. In the …
Growth hormone (GH) and structurally related cytokines regulate a great number of physiological and pathological processes. They do this by coupling their single transmembrane domain (TMD) receptors to cytoplasmic tyrosine kinases, either as homodimers or heterodimers. Recent studies have revealed that many of these receptors exist as constitutive dimers rather than being dimerized as a consequence of ligand binding, which has necessitated a new paradigm for describing their activation process. In the present study, we describe a model for activation of the tyrosine kinase Janus kinase 2 (JAK2) by the GH receptor homodimer based on biochemical data and molecular dynamics simulations. Binding of the bivalent ligand reorientates and rotates the receptor subunits, resulting in a transition from a form with parallel TMDs to one where the TMDs separate at the point of entry into the cytoplasm. This movement slides the pseudokinase inhibitory domain of one JAK kinase away from the kinase domain of the other JAK within the receptor dimer–JAK complex, allowing the two kinase domains to interact and trans-activate. This results in phosphorylation and activation of STATs and other signalling pathways linked to this receptor which then regulate postnatal growth, metabolism and stem cell activation. We believe that this model will apply to most if not all members of the class I cytokine receptor family, and will be useful in the design of small antagonists and agonists of therapeutic value.
portlandpress.com